NICE publishes latest drug decisions

The National Institute of Clinical Excellence (NICE) has issued its latest decisions on the use of drugs on the NHS in England and Wales.

The agency has accepted denosumab for restricted use in the prevention of osteoporotic fragility fractures in postmenopausal women. Liraglutide, at a daily dose of 1.2mg, is accepted for restricted use in dual and triple therapy of patients with type 2 diabetes.

NICE was unable to recommend bendamustine for the treatment of indolent rituximab-resistant non-Hodgkin’s lymphoma because no supporting evidence was submitted. For the same reason, temsirolimus could not be recommended for the treatment of relapsed or refractory mantle cell lymphoma.

The agency also rejected ofatumumab for the treatment of chronic lymphocytic leukaemia that is refractory to fludarabine and alemtuzumab; omalizumab for severe persistent allergic asthma in children aged 6 to 11 years; and eltrombopag for chronic immune (idiopathic) thrombocytopenic purpura.